Intermittent Use of Aerosolized Ribavirin for Treatment of RSV
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
1. To determine whether aerosolized ribavirin is effective when given at an intermittent
dose over 3 hours every 8 hours for therapy of RSV upper respiratory tract infection
(URI) and whether it can prevent progression to pneumonia.
2. To determine the effect of this regimen on persistence of viral shedding.